Literature DB >> 21823193

Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy.

Helle Wallach Kildemoes1, Carsten Hendriksen, Morten Andersen.   

Abstract

PURPOSE: To develop a pharmacoepidemiologic method for drug utilization analysis according to indication, gender, and age by means of register-based information. Statin utilization in 2005 was applied as an example.
METHODS: Following the recommendations for statin therapy, we constructed an indication hierarchy with eight mutually exclusive levels of register markers of cardiovascular disease and diabetes. Danish residents, as of January 1, 1996, were followed at the individual level in nationwide registers with respect to dispensed prescriptions of cardiovascular drugs and antidiabetics (1996-2005) along with discharge diagnoses and surgical procedures (1977-2005). The highest current possible indication level was assigned to all cohort members. Stratified by indication, gender, and age, statin treatment prevalence and incidence were calculated.
RESULTS: Statin treatment prevalence was highest among individuals with myocardial infarction and tended to be higher among men with indications in the upper part of the hierarchy, but it was higher among women (especially the elderly) in the lower part of the hierarchy. Treatment incidence rates followed roughly the same pattern. Women with no register marker or primary hypertension accounted for almost 50% of all incident female users; among men, the figure was 35%. The proportion of incident users with ischemic heart disease or myocardial infarction increased with age.
CONCLUSION: The proposed indication hierarchy provided new insight into prescription patterns of statins. The method can be implemented for other drug categories and could be useful for studying trends in drug utilization, differential drug adherence, and cross-national comparisons.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21823193     DOI: 10.1002/pds.2195

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  15 in total

1.  Do immigrants from Turkey, Pakistan and Ex-Yugoslavia with newly diagnosed type 2 diabetes initiate recommended statin therapy to the same extent as Danish-born residents? A nationwide register study.

Authors:  Diana C Sanchez-Ramirez; Allan Krasnik; Helle Wallach Kildemoes
Journal:  Eur J Clin Pharmacol       Date:  2012-05-31       Impact factor: 2.953

2.  Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.

Authors:  Anna Citarella; Marie Linder; Helle Kieler; Ingegärd Anveden Berglind; Anders Sundström; Björn Wettermark; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2015-12-16       Impact factor: 2.953

3.  Use of statins in the elderly according to age and indication-a cross-sectional population-based register study.

Authors:  Helena Sundvall; Johan Fastbom; Susanna M Wallerstedt; Sigurd Vitols
Journal:  Eur J Clin Pharmacol       Date:  2019-03-03       Impact factor: 2.953

4.  Family history of cardiovascular disease and influence on statin therapy persistence.

Authors:  Anna Citarella; Helle Kieler; Anders Sundström; Marie Linder; Björn Wettermark; Ingegärd Anveden Berglind; Morten Andersen
Journal:  Eur J Clin Pharmacol       Date:  2014-03-08       Impact factor: 2.953

5.  Statin use among older Finns stratified according to cardiovascular risk.

Authors:  Eveliina Upmeier; Maarit Jaana Korhonen; Arja Helin-Salmivaara; Risto Huupponen
Journal:  Eur J Clin Pharmacol       Date:  2012-06-17       Impact factor: 2.953

6.  Familial Resemblance in Low-Density Lipoprotein Cholesterol Response to Statins in the Danish Population.

Authors:  Giulia Corn; Marie Lund; Mark A Hlatky; Jan Wohlfahrt; Mads Melbye
Journal:  J Am Heart Assoc       Date:  2022-05-27       Impact factor: 6.106

7.  Adherence to preventive statin therapy according to socioeconomic position.

Authors:  Helle Wallach-Kildemoes; Morten Andersen; Finn Diderichsen; Theis Lange
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

8.  Sociodemographic and diagnostic characteristics of prescribing a second-line lipid-lowering medication: ezetimibe used as initial medication, switch from statins, or add-on medication.

Authors:  Helle Wallach-Kildemoes; Ebba Holme Hansen
Journal:  Eur J Clin Pharmacol       Date:  2015-07-31       Impact factor: 2.953

9.  Accumulation of cardiovascular and diabetes medication among apparently healthy statin initiators.

Authors:  Piia Lavikainen; Maarit Jaana Korhonen; Risto Huupponen; Arja Helin-Salmivaara
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

10.  Is the high-risk strategy to prevent cardiovascular disease equitable? A pharmacoepidemiological cohort study.

Authors:  Helle Wallach-Kildemoes; Finn Diderichsen; Allan Krasnik; Theis Lange; Morten Andersen
Journal:  BMC Public Health       Date:  2012-08-04       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.